Danaher Corporation

Core Business

Danaher Corporation, through its Cytiva subsidiary (formerly GE Healthcare Life Sciences), is the leading provider of bioprocessing equipment and automation systems for CGT manufacturing. The Sefia automated cell therapy production platform, developed in partnership with Kite Pharma, represents a breakthrough in closed-system CAR-T manufacturing automation. Cytiva's chromatography systems and cell culture technologies are used in virtually every CGT production facility worldwide.

Global Presence

Danaher operates across 60+ countries with approximately 63,000 employees. Cytiva's 16,000 specialized employees design and manufacture bioprocess equipment across North America, Europe, and Asia. The company's 2025 revenue of $24.6 billion provides substantial resources for continued CGT technology investment.

Key Strengths

Danaher/Cytiva's unique combination of precision manufacturing, automation expertise, and deep CGT industry partnerships enables it to provide the essential production infrastructure for the world's leading cell therapy facilities. The Sefia platform, developed with Kite, has demonstrated a 50% capacity increase in clinical settings. Cytiva's installed base in virtually every GMP cell therapy facility creates significant switching costs for customers.

VerityRank Score

Danaher (Cytiva) achieves a VerityRank Score of 90/100, reflecting its essential equipment provider position, breakthrough automation platform, and deep integration into the global CGT manufacturing infrastructure.